MARKET

GENE

GENE

Genetic Technologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.280
+0.010
+0.79%
Closed 16:00 05/25 EDT
OPEN
1.280
PREV CLOSE
1.270
HIGH
1.290
LOW
1.260
VOLUME
9.45K
TURNOVER
6.01K
52 WEEK HIGH
5.18
52 WEEK LOW
0.9500
MARKET CAP
19.70M
P/E (TTM)
-3.6697
1D
5D
1M
3M
1Y
5Y
Acquisition of global direct to consumer ecommerce business
MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement t...
GlobeNewswire · 05/16 13:00
GOEV, SUNW and APPH among pre market gainers
Rattler Midstream RTLR +14% Diamondback Energy to buy Rattler Midstream in all-stock deal. Spirit Airlines SAVE +14% on new tender offer from JetBlue. AgriFORCE Growing Systems (AGRI) +15%. NanoViricides (NNVC) +14% reports that it has
Seekingalpha · 05/16 12:26
Genetic Technologies to Acquire AffinityDNA for $683,000
MT Newswires · 05/16 11:21
Notable earnings after Wednesday's close
AA, BDN, CCI, CSX, CVNA, EFX, FR, GENE, GL, KALU, KMI, KNX, LBRT, LRCX, LSTR, MMLP, RLI, SAND, SEIC, SLG, SNBR, STLD, THC, TSLA, UAL, UMPQ, VMI, WHR For Seeking
Seekingalpha · 04/19 21:35
Genetic Technologies reports 9M results
Genetic Technologies (NASDAQ:GENE) reported YTD results for the nine months ended March 31. The Australian company said YTD growth in revenue was +475%. Cash receipts of A$2M in Q3, an increase
Seekingalpha · 04/08 12:58
Genetic Technologies drives leadership in precision medicine with Multi-Risk Test
MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for ...
GlobeNewswire · 04/08 12:00
US Patent Office Grants Patent for COVID-19 Risk Test
MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Pate...
GlobeNewswire · 02/23 13:00
Genetic Technologies Wins New US Patent For GeneType COVID-19 Risk Test
MT Newswires · 02/23 11:09
More
No Data
Learn about the latest financial forecast of GENE. Analyze the recent business situations of Genetic Technologies through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
-0.29-0.22-0.14-0.07
2020/12
2020/06
2021/12
2021/06
2022/12
Institutional Holdings
Institutions: 21
Institutional Holdings: 151.76K
% Owned: 0.99%
Shares Outstanding: 15.39M
TypeInstitutionsShares
Increased
2
6.31K
New
3
35.81K
Decreased
4
72.63K
Sold Out
4
53.92K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+0.88%
Healthcare Providers & Services
+0.31%
Key Executives
Chairman/Director
Peter Rubenstein
Chief Executive Officer
Simon Morriss
Chief Financial Officer/Secretary
Michael Tonroe
Corporate Executive
Mark Ostrowski
Chief Operating Officer
Stan Sack
Executive Director
Jerzy Muchnicki
Other
Richard Allman
Other
M. Luisa Ashdown
Other
Susan Gross
Other
Diana Newport
Non-Executive Director
Nick Burrows
Non-Executive Independent Director
Lindsay Wakefield
No Data
No Data
About GENE
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company focuses on the development and commercialization of genetic risk assessment technology for contracting cancer and other chronic diseases. The Company operates through two geographic segments: Australia and United states of America (USA). Australia segment is the home country of the parent entity and the location of the Company's genetic testing and licensing operations. USA segment is the home of Phenogen Sciences Inc. and GeneType Corporation. The Company’s products include GeneType for Breast Cancer is a test that can determine a woman's risk of developing sporadic breast cancer over a period of time; GeneType for Colorectal Cancer is a test that can determine a patient's risk of developing colorectal cancer over a period of time. The Company focuses on development its Germline testing division for hereditary testing.

Webull offers kinds of Genetic Technologies Limited (ADR) stock information, including NASDAQ:GENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GENE stock methods without spending real money on the virtual paper trading platform.